Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

Executive Summary

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.


Related Content

Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Alarm As Novartis Exits Antibiotics Space
Brits Lead Charge In Global Battle Against Antimicrobial Resistant Superbugs
Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe
US FDA Joins Chorus Of Concerns About Results Of GAIN Act
Melinta: A Pure-Play Antibiotics Specialist Rises
Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher
Anti-Infective R&D Ecosystem Getting Healthier, But Trials Remain
EU's "Horizon 2020" to fund innovative drug/diagnostic R&D and boost life sciences industry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts